X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

NXTC

Closed

Nextcure  Inc

0.436
-0.024 (-5.22%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.46
Day's Range: 0.4263 - 0.47
Send
When Written:
 
1.5
NextCure Inc. is a biopharmaceutical company that develops immunotherapy treatments for cancer and other diseases. The company's proprietary platform, FIND-IO, identifies novel immune targets and biomarkers that can be used to develop therapies that modulate the immune system to fight cancer. NextCure's lead product candidate, NC318, is a monoclonal antibody that targets Siglec-15, a protein that is overexpressed in multiple types of cancer. The company is also developing other product candidates, including NC410, which targets immune checkpoint protein VISTA, and NC762, which targets immune checkpoint protein TIM-3. NextCure was founded in 2015 and is headquartered in Beltsville, Maryland.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X